CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, 1090, Vienna, Austria.
Helmholtz Munich, Molecular Targets and Therapeutics Center, Institute of Structural Biology, Neuherberg, 85764, München, Germany.
Nat Commun. 2023 Aug 16;14(1):4504. doi: 10.1038/s41467-023-40124-0.
SMNDC1 is a Tudor domain protein that recognizes di-methylated arginines and controls gene expression as an essential splicing factor. Here, we study the specific contributions of the SMNDC1 Tudor domain to protein-protein interactions, subcellular localization, and molecular function. To perturb the protein function in cells, we develop small molecule inhibitors targeting the dimethylarginine binding pocket of the SMNDC1 Tudor domain. We find that SMNDC1 localizes to phase-separated membraneless organelles that partially overlap with nuclear speckles. This condensation behavior is driven by the unstructured C-terminal region of SMNDC1, depends on RNA interaction and can be recapitulated in vitro. Inhibitors of the protein's Tudor domain drastically alter protein-protein interactions and subcellular localization, causing splicing changes for SMNDC1-dependent genes. These compounds will enable further pharmacological studies on the role of SMNDC1 in the regulation of nuclear condensates, gene regulation and cell identity.
SMNDC1 是一个含有 Tudor 结构域的蛋白,可识别二甲基精氨酸并作为必需的剪接因子控制基因表达。在这里,我们研究了 SMNDC1 Tudor 结构域对蛋白质-蛋白质相互作用、亚细胞定位和分子功能的特定贡献。为了在细胞中扰乱蛋白质功能,我们开发了针对 SMNDC1 Tudor 结构域二甲基精氨酸结合口袋的小分子抑制剂。我们发现 SMNDC1 定位于部分与核斑点重叠的液-液相分离无膜细胞器。这种凝聚行为由 SMNDC1 的无规卷曲 C 端区域驱动,依赖于 RNA 相互作用,并可在体外重现。该蛋白的 Tudor 结构域抑制剂会严重改变蛋白质-蛋白质相互作用和亚细胞定位,导致 SMNDC1 依赖性基因的剪接变化。这些化合物将使我们能够进一步研究 SMNDC1 在核凝聚体、基因调控和细胞身份调节中的作用的药理学。